Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology
France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...
Multi-specific antibodies
Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...
Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...
Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...
Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology
France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...
Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma
US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...
ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) has received approval from the National Medical Products...
CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors
China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...
Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors
Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...
Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...
Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a...
Sunshine Guojian and Shenyang 3SBio License 612 and 708 Programs for Anti-Tumor Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd and Shenyang 3SBio Co., Ltd, both subsidiaries of...
3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China
China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...
LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites
Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...
J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s...
Akeso Completes Enrollment for Global Phase III Trial of Ivonescimab in Lung Cancer
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the global...
Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up...
Chongqing Genrix’s Silevimig NDA Accepted for Rabies Immunization Review
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) has announced that a New Drug...
Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500
China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...